Fri, Mar 6, 2015, 1:11 PM EST - U.S. Markets close in 2 hrs 49 mins


% | $
Quotes you view appear here for quick access.


  • lempe39398 lempe39398 Jan 8, 2013 10:03 PM Flag

    Genzyme specialty is orphan drugs

    look at their products and its annual cost per product, your eyes will pop out. David Meeker has never served as a director of any publicly traded company, Savient is his first. Why does a CEO of a 20 billion dollar company needs to sit on the board of a money bleeding biotech? I am sure its not the 50K Savient is paying him. BTW, in my opinion SVNT can easily triple the price of Krystexxa.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Look what Qcor has done with its price for acthar. Can they do the same thing with K?

      • 1 Reply to frankforwin
      • That's a very interesting analogy.

        "In May 2007, we determined that our sales force driven business strategy was not generating an appropriate return and took action to terminate that strategy. We began the process of examining different strategies to best position Acthar to benefit patients, advance our product development programs, and preserve our capital. As part of this process, we reduced the number of members of our field organization by approximately 70%, announced the departure of our former Chief Executive Officer, and appointed Don Bailey, a member of our board of directors, our Interim President. Mr. Bailey was subsequently appointed President and Chief Executive Officer in November 2007.

        In August 2007, we announced a new strategy and business model for Acthar. In connection with the new strategy, we implemented a new pricing level for Acthar which was effective August 27, 2007. We also expanded our sponsorship of Acthar patient assistance and co-pay assistance programs, which provide an important safety net for uninsured and under-insured patients using Acthar, and established a group of 10 product service consultants and 4 medical science liaisons to work with healthcare providers who administer Acthar. The new strategy, as demonstrated by our 2007 results, has significantly improved our ability to maintain the long-term availability of Acthar and fund important research and development projects. Our total net sales were $49.8 million for the year ended December 31, 2007 as compared to $12.8 million for the year ended December 31, 2006. Our net income before income taxes and the allocation of earnings to preferred stock was $23.0 million for the year ended December 31, 2007 as compared to a loss of $10.1 million for the year ended December 31, 2006. As of December 31, 2007, our cash, cash equivalents and short-term investments totaled $30.2 million as compared to $18.4 million as of December 31, 2006."

0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.